Table 1.
Characteristics of the study patients according to SVR following the first DAA treatment.
Table 2.
Univariate and logistic regression analysis linking failure with independent variables.
Table 3.
Failure rates following the first DAA regimen, by HCV genotype and treatment regimen in patients who completed the 12 weeks post treatment evaluation (n = 3,830 patients).
Table 4.
Patients who received a second DAA treatment, by type of first regimen and HCV genotype (n = 72 patients).
Fig 1.
Modifications of liver disease stage following DAA treatment in patients with cirrhosis.
(A) Baseline, post-failure and post-retreatment SVR12 changes of Child Pugh Class; (B) baseline and post-failure changes of Child Pugh Class for patients who were not retreated yet; (C) baseline and post-SVR12 changes of Child Pugh Class for patients who achieved SVR12 following the first DAA treatment. Bold arrows indicate patients who did not change the Child Pugh Class. Dashed arrows indicate patients who worsened the Child Pugh Class, whereas the grey arrows indicate patients who improved the Child Pugh class. In the curly brackets are reported the number of patients for specific changes observed in the Child Pugh classes in the three points of evaluation. n = number of patients.